Improving islet transplantation for type 1 diabetes treatment
Islet dosing and loading density in injection molded macroencapsulation devices
['FUNDING_SBIR_1'] · IMMUNOSHIELD THERAPEUTICS INC. · NIH-10716174
This study is working on making islet transplantation a better option for people with type 1 diabetes by creating special devices that protect the transplanted cells from the immune system and help them get the oxygen they need to thrive.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | IMMUNOSHIELD THERAPEUTICS INC. (nih funded) |
| Locations | 1 site (CHANDLER, UNITED STATES) |
| Trial ID | NIH-10716174 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of islet transplantation, a potential therapy for type 1 diabetes. It aims to address the challenges of immune response and donor shortages by developing macroencapsulation devices that protect transplanted islets from immune rejection. The study employs advanced computational modeling to design these devices for better oxygen transport, which is crucial for the survival and function of the islets. By improving the safety and efficacy of this treatment, the research seeks to make islet transplantation a more viable option for patients with type 1 diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with type 1 diabetes who may benefit from islet transplantation.
Not a fit: Patients with type 2 diabetes or those who are not candidates for islet transplantation may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective islet transplantation therapies, potentially reducing or eliminating the complications associated with type 1 diabetes.
How similar studies have performed: While there have been promising preclinical studies on islet encapsulation, this specific approach using macroencapsulation devices is still being explored and has not yet achieved widespread clinical success.
Where this research is happening
CHANDLER, UNITED STATES
- IMMUNOSHIELD THERAPEUTICS INC. — CHANDLER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SNIR, OREN — IMMUNOSHIELD THERAPEUTICS INC.
- Study coordinator: SNIR, OREN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.